68.17
Schlusskurs vom Vortag:
$68.39
Offen:
$68.5
24-Stunden-Volumen:
246.23K
Relative Volume:
0.18
Marktkapitalisierung:
$7.23B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
54.11
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
-6.74%
1M Leistung:
-11.20%
6M Leistung:
+13.64%
1J Leistung:
+97.72%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CORT
Corcept Therapeutics Inc
|
68.14 | 7.33B | 628.56M | 141.82M | 142.60M | 1.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.69 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
570.82 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.14 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.96 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-06 | Hochstufung | Truist | Hold → Buy |
2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
2022-08-01 | Herabstufung | Truist | Buy → Hold |
2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
2022-01-28 | Eingeleitet | Truist | Buy |
2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
2019-09-24 | Eingeleitet | Jefferies | Buy |
2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
2018-08-10 | Bestätigt | Stifel | Hold |
2018-05-31 | Herabstufung | Stifel | Buy → Hold |
2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-08-31 | Eingeleitet | Stifel | Buy |
2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
2015-04-21 | Eingeleitet | FBR Capital | Outperform |
2014-01-13 | Herabstufung | Stifel | Buy → Hold |
2013-08-09 | Herabstufung | Janney | Buy → Neutral |
2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance
What analysts say about Corcept Therapeutics Incorporated stockFree Consultation - jammulinksnews.com
What drives Corcept Therapeutics Incorporated stock priceRemarkable growth - jammulinksnews.com
Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Is Corcept Therapeutics Incorporated a good long term investmentTriple-digit wealth increases - Autocar Professional
Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - 富途牛牛
Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView
FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News
M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser
How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals
Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest
Corcept Therapeutics Submits New Drug Application to FDA - TipRanks
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN
Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada
Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
A New Dawn in Diabetes Treatment: Corcept Therapeutics' Korlym and the Untapped $2.8 Billion Opportunity - AInvest
Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada
Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com
Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail
10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener
Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire
Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Nasdaq
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga
Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada
Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada
Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK
Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia
Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News
Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive
Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga
Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):